Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents (Note 7)	$ 6,536.2	$ 4,582.1
Short-term investments (Note 7)	1,497.9	1,456.5
Accounts receivable, net of allowances of $38.7 (2017) and $40.3 (2016)	4,546.3	4,029.4
Other receivables	715.9	736.9
Inventories (Note 6)	4,458.3	3,561.9
Prepaid expenses and other	1,447.5	734.6
Total current assets	19,202.1	15,101.4
Other Assets
Investments (Note 7)	5,678.8	5,207.5
Goodwill (Note 8)	4,370.1	3,972.7
Other intangibles, net (Note 8)	4,029.2	4,357.9
Sundry	2,874.3	1,913.8
Total other assets	16,952.4	15,451.9
Property and equipment, net (Note 9)	8,826.5	8,252.6
Total assets	44,981.0	38,805.9
Current Liabilities
Short-term borrowings and current maturities of long-term debt (Note 10)	3,706.6	1,937.4
Accounts payable	1,410.7	1,349.3
Employee compensation	997.9	896.9
Sales rebates and discounts	4,465.1	3,914.9
Dividends payable	590.6	548.1
Income taxes payable (Note 13)	532.9	119.1
Other current liabilities	2,832.1	2,220.9
Total current liabilities	14,535.9	10,986.6
Other Liabilities
Long-term debt (Note 10)	9,940.5	8,367.8
Accrued retirement benefits (Note 14)	3,513.9	2,453.9
Long-term income taxes payable (Note 13)	3,776.5	688.9
Other noncurrent liabilities	1,546.3	2,228.2
Total other liabilities	18,777.2	13,738.8
Eli Lilly and Company Shareholders' Equity (Notes 11 and 12)
Common stock—no par value Authorized shares: 3,200,000 Issued shares: 1,100,672 (2017) and 1,101,586 (2016)	687.9	688.5
Additional paid-in capital	5,817.8	5,640.6
Retained earnings	13,894.1	16,046.3
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss (Note 16)	(5,718.6)	(5,274.0)
Cost of common stock in treasury	(75.8)	(80.5)
Total Eli Lilly and Company shareholders' equity	11,592.2	14,007.7
Noncontrolling interests	75.7	72.8
Total equity	11,667.9	14,080.5
Total liabilities and equity	$ 44,981.0	$ 38,805.9